AFASAK

AFASAK

A primary prevention study comparing low-dose aspirin to warfarin anticoagulation in preventing thromboembolic phenomena (stroke, TIA, or embolic complications) of chronic atrial fibrillation.
Conclusion Thromboembolism was much lower with warfarin (2.0% per year) than with aspirin (5.5% per year) or placebo.
Mentioned in ?
References in periodicals archive ?
Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study.
Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study.
Warfarin, aspirin ve plasebonun karsilastirildigi AFASAK, SPAF I, BAATAF, SPINAF, EAFT, SPAF II calismalarinda, warfarin ve aspirin tedavilerinin her birinin plaseboya gore strok riskini anlamli azalttigi, warfarinin ise aspirin ile karsilastirildiginda cok daha iyi sonuclar verdigini gostermistir (1).
There are obvious differences between these study cohorts[4, 5]; the AFASAK study cohort had a higher prevalence of cardiac failure and myocardial infarction and over half were aged over 74 years[4].